Intestinal Cancer
Return to Library
|
Free Intestinal Cancer Articles |
|
|
|
|
Studies from A.E. Snook et al provide new data on immunotherapy
2009 JUN 8 - (NewsRx.com) -- "Cancer mucosa antigens are emerging as a new category of self-antigens expressed normally in immunologically privileged mucosal compartments and universally by their derivative tumor. These antigens leverage the established immunologic partitioning of systemic and mucosal compartments, limiting tolerance opposing systemic antitumor efficacy," researchers in the United States report. "An unresolved issue surrounding self-antigens as immunotherapeutic targets is autoinmmunity following systemic immunization. In the context of cancer mucosa antigens, immune effectors to self-antigens risk amplifying mucosal inflammatory disease promoting carcinogenesis. Here, we examined the relationship between immunotherapy for systemic colon cancer metastases targeting the intestinal cancer mucosa antigen guanylyl cyclase C (GCC) and its effect on inflammatory bowel disease and carcinogenesis in mice. Immunization with GCC-expressing viral vectors opposed nascent tumor growth in mouse models of pulmonary metastasis, reflecting systemic lineage-specific tolerance characterized by CD8(+), but not CD4(+), T-cell or antibody responses. Responses protecting against systemic metastases spared intestinal epithelium from autoimmunity, and systemic GCC immunity did not amplify chemically induced inflammatory bowel disease. Moreover, GCC immunization failed to promote intestinal carcinegenesis induced by germ-line mutations or chronic inflammation. The established role of CD8(+) T cells in antitumor efficacy, but CD4(+) T cells in autoimmunity, suggests that lineage-specific responses to GCC are particularly advantageous to;protect against systemic metastases without mucosal inflammation," wrote A.E. Snook and colleagues. The researchers concluded: "These observations support the utility of GCC-targeted immunotherapy in patients at risk for systemic metastases, including those with inflammatory bowel disease, hereditary colorectal cancer syndromes, and sporadic colorectal cancer, [Cancer Res 2009;69(8):3537-44]'." Snook and colleagues published their study in Cancer Research (Lineage-Specific T-Cell Responses to Cancer Mucosa Antigen Oppose Systemic Metastases without Mucosal Inflammatory Disease. Cancer Research, 2009;69(8):3537-3544). For additional information, contact S.A. Waldman, 132 S 10th Street, Philadelphia, PA 19107, USA. Publisher contact information for the journal Cancer Research is: American Association Cancer Research, 615 Chestnut St., 17TH Floor, Philadelphia, PA 19106-4404, USA. Keywords: United States, Street, Biological Therapy, Cancer Research, Carcinogenesis, Colon Cancer, Colon Carcinoma, Cyclase, Enzyme Research, Gastroenterology, Immunotherapy, Inflammatory Bowel Disease, Intestinal Cancer, Intestinal Neoplasms, Oncology, Treatment. This article was prepared by Biotech Business Week editors from staff and other reports. Copyright 2009, Biotech Business Week via NewsRx.com.
|
